Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

mAbs

Showing results (1701-1710 of 1,779) with videos related to

Pageof 178
Sort By:
Mabs|August 8, 2025
Enhanced rational protein engineering to reduce viscosity in high-concentration IgG1 antibody solutionsTyler J Lefevre, Jenna G Caldwell, Austin Gallegos, et al.
Mabs|May 25, 2021
Ensembles in solution as a new paradigm for antibody structure prediction and designMonica L Fernández-Quintero, Guy Georges, Janos M Varga, et al.
Mabs|July 11, 2025
Innovative strategies for T cell engagers for cancer immunotherapyCristina Bergamaschi, Miguel Gaspar, Thomas Ciucci, et al.
Mabs|July 22, 2025
AlphaBind, a domain-specific model to predict and optimize antibody-antigen binding affinityAditya A Agarwal, James Harrang, David Noble, et al.
Mabs|December 16, 2025
P329G-engager: a universal mix & match antibody-based adaptor platform for cancer immunotherapyMarlena Surowka, Diana Darowski, Idil Hutter-Karakoc, et al.
Mabs|December 14, 2025
Targeted dual selection to optimize transposon stable pool generation of multispecificsJulie Johnston, Sonja Tierson, Yuyan Xu, et al.
Mabs|December 8, 2025
Functional NK engagers from OmniClic, a common light-chain platform producing fully human-sequence antibodies in a chicken host speciesBaisen Zeng, Ingrid Mechin, David Mowrey, et al.
Mabs|December 17, 2024
T cell margination: investigating the detour of T cells following forimtamig treatment in humanized miceNils O'Brien, Joerg P J Mueller, Ann-Marie E Bröske, et al.
Mabs|January 24, 2025
Engineered ipilimumab variants that bind human and mouse CTLA-4Brett Robison, S J Diong, Anusha Kumar, et al.
Mabs|February 18, 2025
Achieving Acceleration to First-in-Human: MSD's Learnings on Platform Method Validation StrategyXiaoqing Hua, Jorge Quiroz, Joop Waterval, et al.
Pageof 178

Showing results (1701-1710 of 1,779) with videos related to

Sort By:
Pageof 178
Mabs|August 8, 2025
Enhanced rational protein engineering to reduce viscosity in high-concentration IgG1 antibody solutionsTyler J Lefevre, Jenna G Caldwell, Austin Gallegos, et al.
Mabs|May 25, 2021
Ensembles in solution as a new paradigm for antibody structure prediction and designMonica L Fernández-Quintero, Guy Georges, Janos M Varga, et al.
Mabs|July 11, 2025
Innovative strategies for T cell engagers for cancer immunotherapyCristina Bergamaschi, Miguel Gaspar, Thomas Ciucci, et al.
Mabs|July 22, 2025
AlphaBind, a domain-specific model to predict and optimize antibody-antigen binding affinityAditya A Agarwal, James Harrang, David Noble, et al.
Mabs|December 16, 2025
P329G-engager: a universal mix & match antibody-based adaptor platform for cancer immunotherapyMarlena Surowka, Diana Darowski, Idil Hutter-Karakoc, et al.
Mabs|December 14, 2025
Targeted dual selection to optimize transposon stable pool generation of multispecificsJulie Johnston, Sonja Tierson, Yuyan Xu, et al.
Mabs|December 8, 2025
Functional NK engagers from OmniClic, a common light-chain platform producing fully human-sequence antibodies in a chicken host speciesBaisen Zeng, Ingrid Mechin, David Mowrey, et al.
Mabs|December 17, 2024
T cell margination: investigating the detour of T cells following forimtamig treatment in humanized miceNils O'Brien, Joerg P J Mueller, Ann-Marie E Bröske, et al.
Mabs|January 24, 2025
Engineered ipilimumab variants that bind human and mouse CTLA-4Brett Robison, S J Diong, Anusha Kumar, et al.
Mabs|February 18, 2025
Achieving Acceleration to First-in-Human: MSD's Learnings on Platform Method Validation StrategyXiaoqing Hua, Jorge Quiroz, Joop Waterval, et al.
Pageof 178